Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 64

1.

A LHCB9-dependent photosystem I megacomplex induced under low light in Physcomitrella patens.

Pinnola A, Alboresi A, Nosek L, Semchonok D, Rameez A, Trotta A, Barozzi F, Kouřil R, Dall'Osto L, Aro EM, Boekema EJ, Bassi R.

Nat Plants. 2018 Nov;4(11):910-919. doi: 10.1038/s41477-018-0270-2. Epub 2018 Oct 29.

PMID:
30374091
2.

Organization of Plant Photosystem II and Photosystem I Supercomplexes.

Kouřil R, Nosek L, Semchonok D, Boekema EJ, Ilík P.

Subcell Biochem. 2018;87:259-286. doi: 10.1007/978-981-10-7757-9_9.

PMID:
29464563
3.

Molecular Mechanisms of Photoadaptation of Photosystem I Supercomplex from an Evolutionary Cyanobacterial/Algal Intermediate.

Haniewicz P, Abram M, Nosek L, Kirkpatrick J, El-Mohsnawy E, Olmos JDJ, Kouřil R, Kargul JM.

Plant Physiol. 2018 Feb;176(2):1433-1451. doi: 10.1104/pp.17.01022. Epub 2017 Nov 29.

4.

Investigation of Pump Compatibility of Fast-Acting Insulin Aspart in Subjects With Type 1 Diabetes.

Zijlstra E, Demissie M, Graungaard T, Heise T, Nosek L, Bode B.

J Diabetes Sci Technol. 2018 Jan;12(1):145-151. doi: 10.1177/1932296817730375. Epub 2017 Sep 18.

5.

Pharmacokinetic Properties of Fast-acting Insulin Aspart Administered in Different Subcutaneous Injection Regions: Response to the commentary by Nuggehally R. Srinivas.

Heise T, Hövelmann U, Nosek L, Sassenfeld B, Thomsen KMD, Haahr H.

Clin Drug Investig. 2017 Sep;37(9):885-887. doi: 10.1007/s40261-017-0539-7. No abstract available.

PMID:
28597216
6.

Insulin degludec: Lower day-to-day and within-day variability in pharmacodynamic response compared with insulin glargine 300 U/mL in type 1 diabetes.

Heise T, Nørskov M, Nosek L, Kaplan K, Famulla S, Haahr HL.

Diabetes Obes Metab. 2017 Jul;19(7):1032-1039. doi: 10.1111/dom.12938. Epub 2017 Apr 23.

7.

Pharmacokinetic Properties of Fast-Acting Insulin Aspart Administered in Different Subcutaneous Injection Regions.

Hövelmann U, Heise T, Nosek L, Sassenfeld B, Thomsen KMD, Haahr H.

Clin Drug Investig. 2017 May;37(5):503-509. doi: 10.1007/s40261-017-0499-y.

8.

Similar pharmacokinetics and pharmacodynamics of rapid-acting insulin lispro products SAR342434 and US- and EU-approved Humalog in subjects with type 1 diabetes.

Kapitza C, Nowotny I, Lehmann A, Bergmann K, Rotthaeuser B, Nosek L, Becker RHA.

Diabetes Obes Metab. 2017 May;19(5):622-627. doi: 10.1111/dom.12856. Epub 2017 Feb 9.

PMID:
27987252
9.

Pharmacokinetic and Pharmacodynamic Properties of Faster-Acting Insulin Aspart versus Insulin Aspart Across a Clinically Relevant Dose Range in Subjects with Type 1 Diabetes Mellitus.

Heise T, Stender-Petersen K, Hövelmann U, Jacobsen JB, Nosek L, Zijlstra E, Haahr H.

Clin Pharmacokinet. 2017 Jun;56(6):649-660. doi: 10.1007/s40262-016-0473-5.

10.

Supercomplexes of plant photosystem I with cytochrome b6f, light-harvesting complex II and NDH.

Yadav KN, Semchonok DA, Nosek L, Kouřil R, Fucile G, Boekema EJ, Eichacker LA.

Biochim Biophys Acta Bioenerg. 2017 Jan;1858(1):12-20. doi: 10.1016/j.bbabio.2016.10.006. Epub 2016 Oct 15.

11.
12.

Structural variability of plant photosystem II megacomplexes in thylakoid membranes.

Nosek L, Semchonok D, Boekema EJ, Ilík P, Kouřil R.

Plant J. 2017 Jan;89(1):104-111. doi: 10.1111/tpj.13325. Epub 2016 Dec 1.

13.

Euglycaemic glucose clamp: what it can and cannot do, and how to do it.

Heise T, Zijlstra E, Nosek L, Heckermann S, Plum-Mörschel L, Forst T.

Diabetes Obes Metab. 2016 Oct;18(10):962-72. doi: 10.1111/dom.12703. Epub 2016 Jul 13. Review.

PMID:
27324560
14.

Evolutionary loss of light-harvesting proteins Lhcb6 and Lhcb3 in major land plant groups--break-up of current dogma.

Kouřil R, Nosek L, Bartoš J, Boekema EJ, Ilík P.

New Phytol. 2016 May;210(3):808-14. doi: 10.1111/nph.13947. Epub 2016 Mar 22.

15.

Light-induced gradual activation of photosystem II in dark-grown Norway spruce seedlings.

Pavlovič A, Stolárik T, Nosek L, Kouřil R, Ilík P.

Biochim Biophys Acta. 2016 Jun;1857(6):799-809. doi: 10.1016/j.bbabio.2016.02.009. Epub 2016 Feb 18.

16.

Metabolic consequences of acute and chronic empagliflozin administration in treatment-naive and metformin pretreated patients with type 2 diabetes.

Muscelli E, Astiarraga B, Barsotti E, Mari A, Schliess F, Nosek L, Heise T, Broedl UC, Woerle HJ, Ferrannini E.

Diabetologia. 2016 Apr;59(4):700-8. doi: 10.1007/s00125-015-3845-8. Epub 2015 Dec 24.

PMID:
26704626
17.

Aleglitazar, a dual peroxisome proliferator-activated receptor-α/γ agonist, improves insulin sensitivity, glucose control and lipid levels in people with type 2 diabetes: findings from a randomized, double-blind trial.

Stirban AO, Andjelkovic M, Heise T, Nosek L, Fischer A, Gastaldelli A, Herz M.

Diabetes Obes Metab. 2016 Jul;18(7):711-5. doi: 10.1111/dom.12620. Epub 2016 Feb 1.

PMID:
26663152
18.

Similar risk of exercise-related hypoglycaemia for insulin degludec to that for insulin glargine in patients with type 1 diabetes: a randomized cross-over trial.

Heise T, Bain SC, Bracken RM, Zijlstra E, Nosek L, Stender-Petersen K, Rabøl R, Rowe E, Haahr HL.

Diabetes Obes Metab. 2016 Feb;18(2):196-9. doi: 10.1111/dom.12588. Epub 2015 Nov 27.

19.

Comparison of the pharmacokinetic and pharmacodynamic profiles of insulin degludec and insulin glargine.

Heise T, Hövelmann U, Nosek L, Hermanski L, Bøttcher SG, Haahr H.

Expert Opin Drug Metab Toxicol. 2015;11(8):1193-201. doi: 10.1517/17425255.2015.1058779. Epub 2015 Jun 18.

PMID:
26086190
20.

Intradermal insulin infusion achieves faster insulin action than subcutaneous infusion for 3-day wear.

Rini CJ, McVey E, Sutter D, Keith S, Kurth HJ, Nosek L, Kapitza C, Rebrin K, Hirsch L, Pettis RJ.

Drug Deliv Transl Res. 2015 Aug;5(4):332-45. doi: 10.1007/s13346-015-0239-x.

21.

Faster-acting insulin aspart: earlier onset of appearance and greater early pharmacokinetic and pharmacodynamic effects than insulin aspart.

Heise T, Hövelmann U, Brøndsted L, Adrian CL, Nosek L, Haahr H.

Diabetes Obes Metab. 2015 Jul;17(7):682-8. doi: 10.1111/dom.12468. Epub 2015 May 8.

22.

Insulin degludec/insulin aspart produces a dose-proportional glucose-lowering effect in subjects with type 1 diabetes mellitus.

Heise T, Nosek L, Klein O, Coester H, Svendsen AL, Haahr H.

Diabetes Obes Metab. 2015 Jul;17(7):659-64. doi: 10.1111/dom.12463. Epub 2015 May 1.

PMID:
25772444
23.

Steady state is reached within 2-3 days of once-daily administration of degludec, a basal insulin with an ultralong duration of action.

Heise T, Korsatko S, Nosek L, Coester HV, Deller S, Roepstorff C, Segel S, Kapur R, Haahr H, Hompesch M.

J Diabetes. 2016 Jan;8(1):132-8. doi: 10.1111/1753-0407.12266. Epub 2015 Mar 24.

PMID:
25581159
24.

Semaglutide, a once-weekly human GLP-1 analog, does not reduce the bioavailability of the combined oral contraceptive, ethinylestradiol/levonorgestrel.

Kapitza C, Nosek L, Jensen L, Hartvig H, Jensen CB, Flint A.

J Clin Pharmacol. 2015 May;55(5):497-504. doi: 10.1002/jcph.443. Epub 2015 Jan 14.

25.

Glucose-lowering effect of insulin degludec is independent of subcutaneous injection region.

Nosek L, Coester HV, Roepstorff C, Thomsen HF, Kristensen NR, Haahr H, Heise T.

Clin Drug Investig. 2014 Sep;34(9):673-9. doi: 10.1007/s40261-014-0218-x.

26.

Distinct Prandial and Basal Glucose-Lowering Effects of Insulin Degludec/Insulin Aspart (IDegAsp) at Steady State in Subjects with Type 1 Diabetes Mellitus.

Heise T, Nosek L, Roepstorff C, Chenji S, Klein O, Haahr H.

Diabetes Ther. 2014 Jun;5(1):255-65. doi: 10.1007/s13300-014-0070-2. Epub 2014 Jun 3.

27.

Impact of injection speed and volume on perceived pain during subcutaneous injections into the abdomen and thigh: a single-centre, randomized controlled trial.

Heise T, Nosek L, Dellweg S, Zijlstra E, Præstmark KA, Kildegaard J, Nielsen G, Sparre T.

Diabetes Obes Metab. 2014 Oct;16(10):971-6. doi: 10.1111/dom.12304. Epub 2014 May 11.

PMID:
24720741
28.

How do nursing students perceive substance abusing nurses?

Boulton MA, Nosek LJ.

Arch Psychiatr Nurs. 2014 Feb;28(1):29-34. doi: 10.1016/j.apnu.2013.10.005. Epub 2013 Oct 17.

PMID:
24506984
29.

Structural characterization of a plant photosystem I and NAD(P)H dehydrogenase supercomplex.

Kouřil R, Strouhal O, Nosek L, Lenobel R, Chamrád I, Boekema EJ, Šebela M, Ilík P.

Plant J. 2014 Feb;77(4):568-76. doi: 10.1111/tpj.12402. Epub 2014 Jan 17.

30.

Modified release terbutaline (SKP1052) for hypoglycaemia prevention: a proof-of-concept study in people with type 1 diabetes mellitus.

Nosek L, Cardot JM, Owens DR, Ibarra P, Bagate K, Vergnault G, Kaiser K, Fischer A, Heise T.

Diabetes Obes Metab. 2012 Dec;14(12):1137-44. doi: 10.1111/dom.12003. Epub 2012 Sep 25.

PMID:
22988932
31.

Continuous glucose monitoring: quality of hypoglycaemia detection.

Zijlstra E, Heise T, Nosek L, Heinemann L, Heckermann S.

Diabetes Obes Metab. 2013 Feb;15(2):130-5. doi: 10.1111/dom.12001. Epub 2012 Sep 20.

PMID:
22974231
32.

Insulin aspart has a shorter duration of action than human insulin over a wide dose-range.

Nosek L, Roggen K, Heinemann L, Gottschalk C, Kaiser M, Arnolds S, Heise T.

Diabetes Obes Metab. 2013 Jan;15(1):77-83. doi: 10.1111/j.1463-1326.2012.01677.x. Epub 2012 Sep 9.

PMID:
22882249
33.

Ultra-long-acting insulin degludec has a flat and stable glucose-lowering effect in type 2 diabetes.

Heise T, Nosek L, Bøttcher SG, Hastrup H, Haahr H.

Diabetes Obes Metab. 2012 Oct;14(10):944-50. doi: 10.1111/j.1463-1326.2012.01638.x. Epub 2012 Jul 10.

34.

Insulin degludec: four times lower pharmacodynamic variability than insulin glargine under steady-state conditions in type 1 diabetes.

Heise T, Hermanski L, Nosek L, Feldman A, Rasmussen S, Haahr H.

Diabetes Obes Metab. 2012 Sep;14(9):859-64. doi: 10.1111/j.1463-1326.2012.01627.x. Epub 2012 Jun 7.

35.

U-100, pH-Neutral formulation of VIAject(®) : faster onset of action than insulin lispro in patients with type 1 diabetes.

Heinemann L, Nosek L, Flacke F, Albus K, Krasner A, Pichotta P, Heise T, Steiner S.

Diabetes Obes Metab. 2012 Mar;14(3):222-7. doi: 10.1111/j.1463-1326.2011.01516.x. Epub 2011 Nov 13.

PMID:
21981286
36.

Automated near-continuous glucose monitoring measured in plasma using mid-infrared spectroscopy.

Jax T, Heise T, Nosek L, Gable J, Lim G, Calentine C.

J Diabetes Sci Technol. 2011 Mar 1;5(2):345-52.

37.

Intradermal microneedle delivery of insulin lispro achieves faster insulin absorption and insulin action than subcutaneous injection.

Pettis RJ, Ginsberg B, Hirsch L, Sutter D, Keith S, McVey E, Harvey NG, Hompesch M, Nosek L, Kapitza C, Heinemann L.

Diabetes Technol Ther. 2011 Apr;13(4):435-42. doi: 10.1089/dia.2010.0184. Epub 2011 Feb 28.

PMID:
21355718
38.

Microneedle-based intradermal versus subcutaneous administration of regular human insulin or insulin lispro: pharmacokinetics and postprandial glycemic excursions in patients with type 1 diabetes.

Pettis RJ, Hirsch L, Kapitza C, Nosek L, Hövelmann U, Kurth HJ, Sutter DE, Harvey NG, Heinemann L.

Diabetes Technol Ther. 2011 Apr;13(4):443-50. doi: 10.1089/dia.2010.0183. Epub 2011 Feb 28.

PMID:
21355716
39.

Critical thinking of nurse managers related to staff RNs' perceptions of the practice environment.

Zori S, Nosek LJ, Musil CM.

J Nurs Scholarsh. 2010 Sep 1;42(3):305-13. doi: 10.1111/j.1547-5069.2010.01354.x.

PMID:
20738741
40.

Novel findings on the metabolic effects of the low glycaemic carbohydrate isomaltulose (Palatinose).

Holub I, Gostner A, Theis S, Nosek L, Kudlich T, Melcher R, Scheppach W.

Br J Nutr. 2010 Jun;103(12):1730-7. doi: 10.1017/S0007114509993874. Epub 2010 Mar 9.

41.

Continuous glucose monitoring during exercise in patients with type 1 diabetes on continuous subcutaneous insulin infusion.

Kapitza C, Hövelmann U, Nosek L, Kurth HJ, Essenpreis M, Heinemann L.

J Diabetes Sci Technol. 2010 Jan 1;4(1):123-31.

42.

Biphasic insulin aspart 30/70: pharmacokinetics and pharmacodynamics compared with once-daily biphasic human insulin and Basal-bolus therapy.

Heise T, Heinemann L, Hövelmann U, Brauns B, Nosek L, Haahr HL, Olsen KJ.

Diabetes Care. 2009 Aug;32(8):1431-3. doi: 10.2337/dc09-0097. Epub 2009 Jun 1.

43.

Changes in basal insulin infusion rates with subcutaneous insulin infusion: time until a change in metabolic effect is induced in patients with type 1 diabetes.

Heinemann L, Nosek L, Kapitza C, Schweitzer MA, Krinelke L.

Diabetes Care. 2009 Aug;32(8):1437-9. doi: 10.2337/dc09-0595. Epub 2009 Jun 1.

44.

PROMAXX inhaled insulin: safe and efficacious administration with a commercially available dry powder inhaler.

Heise T, Brugger A, Cook C, Eckers U, Hutchcraft A, Nosek L, Rave K, Troeger J, Valaitis P, White S, Heinemann L.

Diabetes Obes Metab. 2009 May;11(5):455-9. doi: 10.1111/j.1463-1326.2008.00961.x. Epub 2009 Feb 19.

PMID:
19236443
45.

The pharmacokinetic and pharmacodynamic properties of different formulations of biphasic insulin aspart: a randomized, glucose clamp, crossover study.

Heise T, Eckers U, Kanc K, Nielsen JN, Nosek L.

Diabetes Technol Ther. 2008 Dec;10(6):479-85. doi: 10.1089/dia.2008.0019.

PMID:
19049377
46.

Fluctuation and reproducibility of exposure and effect of insulin glargine in healthy subjects.

Becker RH, Frick AD, Teichert L, Nosek L, Heinemann L, Heise T, Rave K.

Diabetes Obes Metab. 2008 Nov;10(11):1105-13. doi: 10.1111/j.1463-1326.2008.00874.x. Epub 2008 Mar 18.

PMID:
18355326
47.

Dose-response relationship of insulin glulisine in subjects with type 1 diabetes.

Becker RH, Frick AD, Nosek L, Heinemann L, Rave K.

Diabetes Care. 2007 Oct;30(10):2506-7. Epub 2007 Aug 3. No abstract available.

PMID:
17675541
48.

Insulin glulisine: a faster onset of action compared with insulin lispro.

Heise T, Nosek L, Spitzer H, Heinemann L, Niemöller E, Frick AD, Becker RH.

Diabetes Obes Metab. 2007 Sep;9(5):746-53. Epub 2007 Jun 26.

PMID:
17593235
49.
50.

[Mental pain and research].

Nosek L.

Braz J Psychiatry. 2006 Sep;28(3):173-4. Portuguese. No abstract available.

Supplemental Content

Support Center